<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> is an aggressive <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> generally diagnosed after metastatic spread and currently lacks effective medical therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Expression of intracellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1) is an adverse prognostic indicator in various human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and contributes significantly to their metastatic potential </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> therapy reduces circulating ICAM-1 levels in patients with <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> and is associated with reduction in progression from <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We hypothesize that <z:chebi fb="0" ids="35664">statin</z:chebi> therapy may attenuate growth and malignant potential via ICAM-1 expression and nuclear factor-kappa beta activation in human esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Verified human esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells (FLO-1) were treated with <z:chebi fb="0" ids="9150">simvastatin</z:chebi>, <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, or pravastatin (10-, 30-, and 50-Î¼mol/L concentrations) </plain></SENT>
<SENT sid="5" pm="."><plain>3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium <z:chebi fb="25" ids="15858">bromide</z:chebi> viability, 5-<z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-2'-deoxyuridine proliferation, or annexin V <z:mpath ids='MPATH_3'>apoptosis</z:mpath> assays were performed, or cells were stimulated with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha and collected for immunoblotting and flow cytometry </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="9150">Simvastatin</z:chebi> decreased cell viability and proliferation while increasing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in a dose-dependent manner (P &lt; .05) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="9150">Simvastatin</z:chebi> attenuated total cellular and cell-surface ICAM-1 expression as well as nuclear factor-kappa beta activation (P &lt; .05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> had mild effects and pravastatin had essentially no effect on growth and metastatic potential of these cells </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: We demonstrate that treatment of human esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cells with <z:chebi fb="0" ids="9150">simvastatin</z:chebi> attenuates growth, by decreasing cell viability, decreasing cell proliferation, and increasing <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and attenuates metastatic potential, by decreasing expression of key metastatic markers </plain></SENT>
<SENT sid="10" pm="."><plain>These findings identify <z:chebi fb="0" ids="9150">simvastatin</z:chebi> as a potential therapeutic and chemopreventive modality to thwart the progression of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>